secwatch.observer — SEC 8-K summary
======================================

Issuer:     CervoMed Inc. (CRVO)
CIK:        0001053691
Form:       8-K
Filed at:   2025-12-05T23:59:59+00:00
Accession:  0001437749-25-037025
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neflamapimod slows DLB progression in Phase 2b; 89% worsening reduction in key subgroup
--------------------------------------------------------------------------------

- Primary endpoint CDR-SB mean change 52% lower with DP Batch B vs control; 82% lower in patients without AD co-pathology.
- Within-patient comparison vs placebo: 1.12 point improvement on CDR-SB (p=0.005); ADCS-CGIC improved (p=0.004).
- Risk of clinical progression reduced 75%; median time to progression extended from 16 weeks to 1.5 years.
- Plasma GFAP reduced median -16.0 pg/mL (p<0.0001); reduction correlated with clinical treatment response.
- Company planning Phase 3 registrational trial in patients with DLB starting H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053691/000143774925037025/0001437749-25-037025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053691/000143774925037025/crvo20251205_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-037025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer